CorMedix, Inc. CRMD 深 滬
已收盤 09-05 16:00:00 美东时间
12.40
-0.400
-3.12%
華盛通- 最 高12.91
- 今 開12.76
- 成交量 465.97万股
- 最 低 12.35
- 昨 收 12.80
- 總市值 9.23亿
- 52周最高 17.43
- 市盈率 靜 --
- 換手率 6.26%
- 52周最低 5.60
- 委 比 74.90%
- 總股本 7442.92万
- 歷史最高 52.00
- 量 比 0.54
- 振 幅 4.38%
- 歷史最低 0.73
- 每 手 1
- 風險率 2.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多10 Health Care Stocks Whale Activity In Today's Session
This whale alert can help traders discover the next big trading opportunities. ...
09-03 01:35
CorMedix Revised Guidance Of Pro Forma 2025 Combined Revenues To $325M-$350M Vs. Consensus Of $215.14M, Melinta Therapeutics Deal Expected to be near-term accretive to EPS with double-digit accretion expected in 2026
Transaction expected to be near-term accretive to EPS with double-digit accretion expected in 2026; annual run-rate synergies expected to be ~$35 to $45 millionRevised Full Year Financial GuidancePro forma 2025 Revenue:
09-02 19:39
CorMedix Completes Acquisition of Melinta Therapeutics, Raises Financial Guidance and Announces New Leadership Team
CorMedix Inc. announced the completion of its acquisition of Melinta Therapeutics, expanding its portfolio with seven drug products and pipeline opportunities. The deal is expected to generate $325–$350 million in 2025 pro forma revenues and enhance profitability, with potential peak sales for REZZAYO™ prophylaxis exceeding $200 million. Key leadership roles have been finalized, and annual synergies are projected at $35–$45 million. The acquisiti...
09-02 11:30
CorMedix to Participate in Upcoming Investor Conferences
CorMedix Inc. announced that its senior management will participate in fireside chats at the Cantor Global Healthcare Conference on September 5 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 10. CorMedix, a biopharmaceutical company focused on developing life-saving therapeutic products, has successfully commercialized its lead product, DefenCath® (taurolidine and heparin), following FDA approval in November 2023. Th...
08-28 12:30
Elliott Management Bets Against S&P 500, Nasdaq 100, Nvidia Stock In Second Quarter
Elliott Management places new bets against the market in the second quarter, while taking a new long position in Hewlett Packard Enterprise.
08-15 07:24
21.55亿，这家抗生素企业被收购！
（来源：动脉新医药） 当地时间8月7日，生物制药公司CorMedix Inc. (NASDAQ:CRMD)和新型抗生素企业Melinta Therapeuti...
08-08 18:11
Somnigroup International's CorMedix to Acquire Melinta in $300M Deal, Expanding Infectious Disease Portfolio
CorMedix Inc. ("CorMedix") (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, and Melinta Therapeutics LLC ("Melinta"),
08-07 19:14
CorMedix to acquire Melinta Therapeutics, Creating Diversified Specialty Company With Strong Presence in Acute Care Settings
<p> CorMedix announced the acquisition of Melinta Therapeutics for $300 million, expanding its product portfolio with seven innovative hospital-focused infectious disease products and a pipeline with growth potential. The deal is expected to be accretive to EPS in 2026, with annual synergies of ~$35-$45 million. Pro forma 2025 revenues are estimated at $305-$335 million. The transaction advances CorMedix's strategy to build a specialty pharmaceu...
08-07 11:00
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
CorMedix Analyst Says Investors Could Be Further Rewarded
CorMedix boosts Q2 sales forecast as a major dialysis client accelerates DefenCath use, prompting positive analyst coverage and growth outlook.
07-01 02:24
